These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37193239)

  • 1.
    Sadoogh Abbasian S; Ghaznavi-Rad E; Sadelaji S; Abtahi H
    Iran J Microbiol; 2023 Apr; 15(2):243-250. PubMed ID: 37193239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloning, Expression, and Purification of Recombinant Lysostaphin From Staphylococcus simulans.
    Farhangnia L; Ghaznavi-Rad E; Mollaee N; Abtahi H
    Jundishapur J Microbiol; 2014 May; 7(5):e10009. PubMed ID: 25147708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous expression of a truncated form of human recombinant vascular endothelial growth factor-A and its biological activity in wound healing.
    Khaki M; Salmanian AH; Mosayebi G; Baazm M; Babaei S; Molaee N; Abtahi H
    Iran J Basic Med Sci; 2017 Jul; 20(7):791-797. PubMed ID: 28852444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Desbois AP; Gemmell CG; Coote PJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bactericidal effect of lysostaphin coupled with liposomal vancomycin as a dual combating system applied directly on methicillin-resistant
    Hajiahmadi F; Alikhani MY; Shariatifar H; Arabestani MR; Ahmadvand D
    Int J Nanomedicine; 2019; 14():5943-5955. PubMed ID: 31447553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiseptic effect of compound lysostaphin disinfectant and its preventive effect on infection of artificial dermis after graft on full-thickness skin defect wound in rats].
    Jin J; Zhou H; Cui ZC; Wang L; Luo PF; Ji SZ; Hu XY; Ma B; Wang GY; Zhu SH; Xia ZF
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):225-232. PubMed ID: 29690741
    [No Abstract]   [Full Text] [Related]  

  • 7. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
    Becker SC; Foster-Frey J; Donovan DM
    FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staphylococcus simulans Recombinant Lysostaphin: Production, Purification, and Determination of Antistaphylococcal Activity.
    Boksha IS; Lavrova NV; Grishin AV; Demidenko AV; Lyashchuk AM; Galushkina ZM; Ovchinnikov RS; Umyarov AM; Avetisian LR; Chernukha MIu; Shaginian IA; Lunin VG; Karyagina AS
    Biochemistry (Mosc); 2016 May; 81(5):502-10. PubMed ID: 27297900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA).
    Desbois AP; Lang S; Gemmell CG; Coote PJ
    J Appl Microbiol; 2010 Feb; 108(2):723-30. PubMed ID: 19709343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China.
    Yang XY; Li CR; Lou RH; Wang YM; Zhang WX; Chen HZ; Huang QS; Han YX; Jiang JD; You XF
    J Med Microbiol; 2007 Jan; 56(Pt 1):71-76. PubMed ID: 17172520
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Narasimhaswamy N; Bairy I; Shenoy G; Bairy L
    Iran J Microbiol; 2017 Aug; 9(4):208-212. PubMed ID: 29238455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antistaphylococcal activity of bacteriophage derived chimeric protein P128.
    Vipra AA; Desai SN; Roy P; Patil R; Raj JM; Narasimhaswamy N; Paul VD; Chikkamadaiah R; Sriram B
    BMC Microbiol; 2012 Mar; 12():41. PubMed ID: 22439788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus.
    Polak J; Della Latta P; Blackburn P
    Diagn Microbiol Infect Dis; 1993; 17(4):265-70. PubMed ID: 8112040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and characterization of the antibacterial peptidase lysostaphin from Staphylococcus simulans: Adverse influence of Zn
    Chandra Ojha S; Imtong C; Meetum K; Sakdee S; Katzenmeier G; Angsuthanasombat C
    Protein Expr Purif; 2018 Nov; 151():106-112. PubMed ID: 29944958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant production of Trx-Ib-AMP4 and Trx-E50-52 antimicrobial peptides and antimicrobial synergistic assessment on the treatment of methicillin-resistant Staphylococcus aureus under in vitro and in vivo situations.
    Satei P; Ghaznavi-Rad E; Fahimirad S; Abtahi H
    Protein Expr Purif; 2021 Dec; 188():105949. PubMed ID: 34324967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ib-AMP4 antimicrobial peptide as a treatment for skin and systematic infection of methicillin-resistant
    Sadelaji S; Ghaznavi-Rad E; Sadoogh Abbasian S; Fahimirad S; Abtahi H
    Iran J Basic Med Sci; 2022 Feb; 25(2):232-238. PubMed ID: 35655604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.
    Hertlein T; Sturm V; Lorenz U; Sumathy K; Jakob P; Ohlsen K
    Antimicrob Agents Chemother; 2014; 58(3):1630-8. PubMed ID: 24366730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant
    Nour El-Din HT; Elhosseiny NM; El-Gendy MA; Mahmoud AA; Hussein MMM; Attia AS
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32178236
    [No Abstract]   [Full Text] [Related]  

  • 19. MRSA decolonization of cotton rat nares by a combination treatment comprising lysostaphin and the antimicrobial peptide ranalexin.
    Desbois AP; Sattar A; Graham S; Warn PA; Coote PJ
    J Antimicrob Chemother; 2013 Nov; 68(11):2569-75. PubMed ID: 23800902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model.
    Kokai-Kun JF; Chanturiya T; Mond JJ
    J Antimicrob Chemother; 2007 Nov; 60(5):1051-9. PubMed ID: 17848374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.